Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 0.57 |
| ▸ | DYRK1B | Q9Y463 | 9/20 | 0.57 |
| ▸ | DYRK2 | Q92630 | 6/20 | 0.57 |
| ▸ | CLK1 | P49759 | 6/20 | 0.49 |
| ▸ | CLK2 | P49760 | 4/20 | 0.48 |
| ▸ | CLK3 | P49761 | 2/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 4/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.41 |
| ▸ | DYRK4 | Q9NR20 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2142665 | 0.89 | DYRK1A (0.57) | DYRK1ADYRK1BDYRK2CLK1CLK2 | |
| SCHEMBL14103572 | 0.85 | DYRK1A (0.41) | DYRK1ADYRK1BDYRK2CLK1CLK2 | |
| SCHEMBL24773524 | 0.83 | DYRK1A (0.49) | DYRK1ADYRK1BDYRK2CLK1CLK2 | |
| SCHEMBL26223712 | 0.83 | DYRK1A (0.52) | DYRK1ADYRK1BDYRK2CLK1CLK2 | |
| SCHEMBL20558808 | 0.81 | DYRK1A (0.57) | DYRK1ADYRK1BDYRK2CLK1CLK2 | |
| SCHEMBL339129 | 0.81 | DYRK1A (0.61) | DYRK1ADYRK1BDYRK2CLK1CLK2 | |
| SCHEMBL14041199 | 0.80 | DYRK1A (0.53) | DYRK1ADYRK1BDYRK2CLK1CLK2 | |
| SCHEMBL11981321 | 0.78 | CYP3A4 (0.56) | DYRK1ADYRK1BDYRK2CLK1CLK2 | |
| SCHEMBL15965547 | 0.78 | DYRK1A (0.54) | DYRK1ADYRK1BDYRK2CLK1CLK2 | |
| SCHEMBL17821835 | 0.78 | DYRK1A (0.54) | DYRK1ADYRK1BDYRK2CLK1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2238129-B1 | A METHOD FOR THE PREPARATION OF DARIFENACIN HYDROGEN BROMIDE | ZENTIVA KS (CZ) | 2011-08-17 | — | — | EP | disclosed |
| US-20100317871-A1 | METHOD FOR THE PREPARATION OF DARIFENACIN HYDROGEN BROMIDE | ZENTIVA K.S. (CZ) | 2010-12-16 | — | — | US | disclosed |
| US-20100317871-A1 | METHOD FOR THE PREPARATION OF DARIFENACIN HYDROGEN BROMIDE | ZENTIVA K.S. (CZ) | 2010-12-16 | — | — | US | disclosed |
| US-7816539-B2 | Derivatives of benzimidazole and imidazo-pyridine and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2010-10-19 | — | — | US | disclosed |
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2009-10-29 | — | — | US | disclosed |
| WO-2009094957-A1 | A METHOD FOR THE PREPARATION OF DARIFENACIN HYDROGEN BROMIDE | ZENTIVA, K.S. (CZ) | 2009-08-06 | — | — | WO | disclosed |
| US-7501525-B2 | Derivatives of benzimidazole and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-03-10 | — | — | US | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| WO-2008094319-A2 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYTEM (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080139619-A1 | Novel derivatives of benzimidazale and imidazo-pyridine and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS (S.C.R.A.S.) | 2008-06-12 | — | — | US | disclosed |
| WO-2007103754-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| US-7220765-B2 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 2007-05-22 | — | — | US | disclosed |
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | DYRK1A 4784/4885DYRK1B 4801/4885DYRK2 4751/4885 |
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | MC4R, MC3R, MC1R | DYRK1A 1140/4885DYRK1B 1457/4885DYRK2 1181/4885 |
| US-20100317871-A1 | METHOD FOR THE PREPARATION OF DARIFENACIN HYDROGEN BROMIDE | OPRD1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, OPRK1 | DYRK1A 2991/4885DYRK1B 2606/4885DYRK2 2682/4885 |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | DYRK1A 228/4885DYRK1B 268/4885DYRK2 282/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | DYRK1A 258/4885DYRK1B 309/4885DYRK2 355/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | DYRK1A 4471/4885DYRK1B 4558/4885DYRK2 4621/4885 |
| US-20080139619-A1 | Novel derivatives of benzimidazale and imidazo-pyridine and their use as medicaments | MC4R, MC1R, MC3R | DYRK1A 972/4885DYRK1B 1277/4885DYRK2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.